DYADIC startet

Dyadic International Announces Participation In OPTIBIOCAT Collaboration21:20 18.03.14


PR Newswire

JUPITER, Fla., March 18, 2014

JUPITER, Fla., March 18, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new project, "OPTIBIOCAT – Optimized esterase biocatalysts for cost-effective industrial production", an EU-funded project aimed at developing biocatalysts for the cosmetic industry.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Dyadic's Chief Operating Officer, Danai Brooks, stated, "OPTIBIOCAT involves a highly skilled and multidisciplinary partnership of 16 partners from eight EU countries. Our participation in the project further highlights the strength and recognition of our C1 technology platform in producing novel enzymes at commercial scale."

The biocatalysts will be based on feruloyl acid esterases ("FAE") and glucuronyl esterases ("GE") which are expected to be used in the production of phenolic fatty- and sugar- esters with antioxidant activity for the cosmetic industry.  They will also be tested for use in the production of other potential compounds with improved biological activity and properties.  FAE and GE available within the consortium, including those from Dyadic's own proprietary enzyme library, may be improved by site-directed mutagenesis and directed evolution to further improve the desired properties.

Wim van der Wilden, General Manager of Dyadic Netherlands, added "We will utilize both our proprietary C1 enzyme library as well as our patented C1 technology to produce the specific targeted FAE and GE enzymes. In addition, strain improvement and fermentation optimization will then be implemented to reduce production costs and allow for industrial scale production.  Our C1 platform will be a key enabling technology in this large consortium."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce.  Please visit Dyadic's website at www.dyadic.com.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at (www.otcmarkets.com/stock/DYAI/quote).

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, our licensing strategy, research efforts and production capabilities may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) whether the research project will result in any new products; (2) whether the research project will result in any new collaboration or licensing agreements; (3) Dyadic's research and development efforts, and (4) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Initial Information and Disclosure Statement filed with the OTC Markets Group on March 11, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
18.03.14 1,68 1,68 1,61  1,64 $ 10.330 17.006

GrB  

21:20 24.03.14


PR Newswire

JUPITER, Fla., March 24, 2014

JUPITER, Fla., March 24, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,673,618 entitled, "Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose" by the United States Patent and Trademark Office ("USPTO").

(Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

This new patent provides broader intellectual property rights relating to compositions and methods of developing and producing novel enzymes which efficiently convert different sources of plant biomass (e.g. corn stover, wheat straw and bagasse) to fermentable sugars. These sugars can be used in the production of advanced biofuels and bio-based chemicals.

Methods include processes for degrading plant material using enzyme mixtures and specified enzyme combinations. Enzyme compositions are used to break down specific components of plant biomass (e.g. cellulose, hemi-cellulose, and lignin) into a variety of fermentable sugars.

In addition to claims covering the production of these patented enzymes using Dyadic's C1 Expression System, a wide variety of additional production methods are covered including bacteria, yeast, algae, other fungi and plants.

Dyadic's President and CEO, Mark Emalfarb, stated, "Plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce advanced biofuels and bio-based chemicals. This latest patent further broadens our family of patents that address the advanced biofuels and bio-based chemicals market. This latest patent also expands our comprehensive intellectual property portfolio further protecting our C1 Expression System, and the products derived therefrom.  We anticipate that broadening our rights for these applications will allow us to further attract additional blue chip customers, partners, and collaborators."  

This patent is the fourteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and 10 pending U.S. patent applications which cover various features of Dyadic's proprietary technologies.

The newly issued patent is accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce.  Please visit Dyadic's website at www.dyadic.com.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at (www.otcmarkets.com/stock/DYAI/quote).

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, overall IP portfolio and our ability to attract new customers, partners and collaborators may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) whether the patented technology will result in any new products; (2) whether the patented technology will result in any new customers, partners, collaborations or licensing agreements; (3) Dyadic's research and development efforts, (4) Dyadic's ability to successfully enforce its intellectual property rights and (5) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Initial Information and Disclosure Statement filed with the OTC Markets Group on March 11, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire
 

:::::::::::::: 1,54 $ +2,67% +0,04 $
In Euro: 1,1105 € | Nasdaq OTC Other, 25.04.14::::: und schick und SCHÖN  

http://www.ariva.de/news/...-Riley-amp-Co-Investor-Conference-5040492 GrB  

Global Biotechnology Conference
22:25 09.06.14

PR Newswire

JUPITER, Fla., June 9, 2014

JUPITER, Fla., June 9, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced that Dyadic's Chief Operating Officer Danai Brooks will present at the 2014 Global Biotechnology Conference on Wednesday, June 18, 2014 at 4:10 p.m. ET at the John B. Hynes Memorial Convention Center in Boston, Massachusetts. For registration information, please visit the conference website at http://www.globalbiotechcongress.com.

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Mr. Brooks will conduct one-on-one meetings throughout the conference dates of June 16 – 19, 2014. Attendees can contact Dyadic investor relations to arrange a meeting.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote  .

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

Dyadic Appoints Michael Tarnok, Chairman Of Keryx And Former Pfizer Senior Vice President, To Board Of Directors
15:20 12.06.14

PR Newswire

JUPITER, Fla., June 12, 2014

JUPITER, Fla., June 12, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok to the company's Board of Directors.  Mr. Tarnok will also serve on the company's audit and compensation committees.

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing. He is the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc., a biotechnology company focused on the development of therapeutics for renal disease. Prior to joining Keryx in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing.  From 2000-2007, he served as Senior Vice President in Pfizer's U.S. Pharmaceuticals Division.  Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America.  Mr. Tarnok earned an MBA in marketing from New York University and a Bachelors of Science in accounting from St. John's University.  He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.

Mark Emalfarb, Chairman and Chief Executive Officer of Dyadic said, "We are excited for Michael to join the Dyadic board while we continue to execute on our plans to leverage the C1 technology platform, grow our enzyme business and become a fully reporting SEC company.  Having led Keryx, a company with a market capitalization over $1 billion, Mr. Tarnok has a proven track record as a forward thinking and accomplished leader. As Dyadic further ventures into new pharmaceutical applications, Mike's wealth of knowledge in drug development, manufacturing, marketing and finance will be invaluable."

Mr. Tarnok added, "I am impressed with the breadth, scope and number of Dyadic's business opportunities in the company's pipeline. The C1 technology platform is already being applied across multiple markets to develop and manufacture enzymes and other proteins to help feed, fuel and heal the world. Dyadic's licensees and collaborators, such as BASF and Abengoa, are global leaders in the industrial enzyme and biofuel markets. The C1 technology also has the potential to breakthrough as a disruptive manufacturing system for large molecule drugs such as vaccines, monoclonal antibodies and other therapeutic proteins. I look forward to sharing my knowledge and experience with the Dyadic team as they continue to execute on their strategic plans for growth."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

Dyadic Appoints Michael Tarnok, Chairman Of Keryx And Former Pfizer Senior Vice President, To Board Of Directors
15:20 12.06.14

PR Newswire

JUPITER, Fla., June 12, 2014

JUPITER, Fla., June 12, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok to the company's Board of Directors.  Mr. Tarnok will also serve on the company's audit and compensation committees.

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Mr. Tarnok has extensive experience in the pharmaceutical industry across many key areas including finance, operations and marketing. He is the current Chairman and former Interim CEO of Keryx Biopharmaceuticals, Inc., a biotechnology company focused on the development of therapeutics for renal disease. Prior to joining Keryx in 2007, Mr. Tarnok spent the majority of his career at Pfizer Inc., joining in 1989 as Director of Finance for U.S. Manufacturing.  From 2000-2007, he served as Senior Vice President in Pfizer's U.S. Pharmaceuticals Division.  Prior to joining Pfizer, he worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation, and Olivetti Corporation of America.  Mr. Tarnok earned an MBA in marketing from New York University and a Bachelors of Science in accounting from St. John's University.  He also serves on the Board of the Global Health Counsel, a Washington, D.C.-based NGO.

Mark Emalfarb, Chairman and Chief Executive Officer of Dyadic said, "We are excited for Michael to join the Dyadic board while we continue to execute on our plans to leverage the C1 technology platform, grow our enzyme business and become a fully reporting SEC company.  Having led Keryx, a company with a market capitalization over $1 billion, Mr. Tarnok has a proven track record as a forward thinking and accomplished leader. As Dyadic further ventures into new pharmaceutical applications, Mike's wealth of knowledge in drug development, manufacturing, marketing and finance will be invaluable."

Mr. Tarnok added, "I am impressed with the breadth, scope and number of Dyadic's business opportunities in the company's pipeline. The C1 technology platform is already being applied across multiple markets to develop and manufacture enzymes and other proteins to help feed, fuel and heal the world. Dyadic's licensees and collaborators, such as BASF and Abengoa, are global leaders in the industrial enzyme and biofuel markets. The C1 technology also has the potential to breakthrough as a disruptive manufacturing system for large molecule drugs such as vaccines, monoclonal antibodies and other therapeutic proteins. I look forward to sharing my knowledge and experience with the Dyadic team as they continue to execute on their strategic plans for growth."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

Bioeconomy Stocks
22:15 16.06.14

PR Newswire

JUPITER, Fla., June 16, 2014

JUPITER, Fla., June 16, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today that Biofuels Digest has selected Dyadic to be included in its Biofuel Digest Index as part of the annual rebalancing of publicly traded stocks included in the index.

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Danai Brooks, Chief Operating Officer of Dyadic, noted, "Dyadic has gained significant momentum as a critical technology component in the biofuel and bio-based chemical economy.  Earlier this year, Biofuel Digest named Dyadic in the 50 Hottest Companies in Bioenergy.  Abengoa Bioenergy, a Dyadic technology licensee, is opening a first-of-its-kind cellulosic 25 million gallon biofuel plant in Hugoton, Kansas in early July.  We believe that our class-leading enzyme technology and on-site licensing model are the right mix to be successful in this industry."

Biofuel Digest is the world's most widely read biofuel daily covering bioenergy production, finance, policy and research. The Biofuel Digest Index has tracked the bioeconomy since August 2007. Stocks are weighted to reflect market cap, and the extent to which diversified industrial companies are focused on a bio-based strategy.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

Dyadic International Announces Participation In Bakenzyme Project
22:20 09.07.14

PR Newswire

JUPITER, Fla., July 9, 2014

JUPITER, Fla., July 9, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new Bakenzyme project. In collaboration with several industry partners, the Bakenzyme project seeks to develop a novel, pure and widely applicable xylanase-oxidase enzyme product for the baking industry.

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Dyadic's Chief Operating Officer, Danai Brooks, stated, "The aim of this project is to create an enzyme product that improves the structure of bread and increases the bioavailability of health components naturally present in flour. Baking enzymes are a large and growing market. We expect the global baking enzyme market to approach $700 million in five years and believe there is a distinct need for dedicated enzyme mixtures without the negative side activities of products currently available to bakeries."

Enzymes are widely used today by industrial bakeries to increase the stability and rising power of dough, improve crumb structure, increase volume and prevent staling. International bans on the widely popular and highly effective chemical oxidizing agent potassium bromate created the need for safe, yet effective, alternatives. However, most existing enzyme products, such as the currently used glucose oxidase (GOX), are less effective and contain side activities, which can negatively impact bread quality.

Dr. Sandra Hinz, Dyadic's Head of New Product Development, stated, "The novel enzyme mixtures we are developing within the Bakenzyme project will allow manufacturers to combine the benefits of multiple enzymes, improve overall performance and eliminate unwanted side effects without the need for additional additives. As a result consumers can expect consistently higher quality bread with improved texture and more sustainable ingredients. Dyadic's participation in this important program highlights the capabilities of our C1 Expression System to develop innovative products.  Participation in the Bakenzyme project and other private-public programs helps us advance our technology platform and increase the breadth of our enzyme library, which may have applications in a wide variety of industries."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce.  For further information, please visit Dyadic's website at www.dyadic.com.  Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, research efforts, the need for dedicated enzyme mixtures, consumer experience and our successful production of enzymes with minimal negative side activities may constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements to reflect actual results, any changes in expectations or any change in events.

SOURCE Dyadic International, Inc.


Quelle: PR Newswire  

Börsenbucheinsicht
http://www.ariva.de/...c.__dl-,001-aktie/times_and_sales?boerse_id=83 GrB  

RTK 1,57 $ RTP +1,29 Pott +74,44% ,GrB
 

http://www.ariva.de/news/...Dyadic-as-Chief-Financial-Officer-5117005 GrB  

http://www.ariva.de/news/...e-Call-On-Thursday-August-14-2014-5120603 GrB  

http://www.ariva.de/news/...ond-Generation-Biofuel-Technology-5123800 GrB  

http://www.ariva.de/news/...Reports-Q2-2014-Financial-Results-5135446 GrB  

::::::::::::::::::: 1,85 $ +8,82% +0,15 $
In Euro: 1,3806 € | Nasdaq OTC Other, 15.08.14::::::: wowwwwww ..::hopshops  

SK 1,85 $ SKP +8,82 Pott +105,56% ,GrB
 

http://www.ariva.de/news/...es-Form-10-Registration-Statement-5137498 GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  18.08.14      1,87      1,87§1,75 1,75 $ 113.675 205 T

GrB  

Eine Absicherung, bei der die Kauf- oder Verkaufslimits jeweils dynamisch an den jeweiligen Kurs angepasst werden, nennt man dynamische Absicherung. Beispielsweise könnte man mit einer solchen Absicherung einen Stopp-Kurs von 5% unter dem aktuellen Kurs festlegen. http://www.ariva.de/extras/lexikon.m?begriff=Dynamische_Absicherung
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.01.15      0,94    0,9799§0,94 0,9799 $ 7.123 6.782

GrB  

Buch dazu
http://www.ariva.de/...c.__dl-,001-aktie/times_and_sales?boerse_id=83 GrB  

Buch
http://www.ariva.de/...c.__dl-,001-aktie/times_and_sales?boerse_id=83 GrB  

:::::::::::::::::::: 0,98 $ +2,08% +0,02 $
In Euro: 0,8762 € | Nasdaq OTC Other, 28.08.15 ,GrB